HBV quasispecies composition in Lamivudine-failed chronic hepatitis B patients and its influence on virological response to Tenofovir-based rescue therapy.
Introduction: Primary LMV resistance mutation has been mapped in the reverse transcriptase (RT) domain of HBV Pol and typically involved rtM204I/V, while compensatory mutations rtL180M, rtV173L, and rtL80I are often co-selected during therapy to restore HBV replication efficacy.
Result: After implementing Benjamini-Hochberg correction, 3 (rtM204I, rtL80I, rtY54H) out these 7
Mutations associated with drug resistance and prevalence of vaccine escape mutations in patients with chronic hepatitis B infection.
Abstract: Six patients (7%) exhibited resistance mutations to LAM, ETV, and TDF: two with patterns L180M + M204V and four with other different patterns: L80I + L180M + M204I; L80V + L180M + M204V; M204I; A194T.
Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy.
Discussion: However, we did not observe associated rtL80I substitutions by sequencing in our cases.
Discussion: In this regard, the rtL80I was shown to be associated with restoring viral replication and increasing drug resistance properties of LAM-resistant isolates with impaired replication.
HBV Drug Resistance Substitutions Existed before the Clinical Approval of Nucleos(t)ide Analogues: A Bioinformatic Analysis by GenBank Data Mining.
Introduction: According to several clinical practice guidelines and authoritative reviews, NUCr substitutions can be classified into two categories: primary NUCr substitutions at 8 codons (rtI169T, rtA181T/V, rtT184A/C/F/G/I/L/M/S, rtA194T, rtS202C/G/I, rtM204I/V, rtN236T and rtM250I/L/V) and secondary substitutions at 3 codons in RT<
[Drug-resistant mutations in hepatitis B virus found in chronic HBV carriers using PCR sequencing technology].
Abstract: Each of the NAs had dominant drug-resistant mutational profiles, with rtM204I+rtL180M+-rtL80I (30.9%) for LAM, rtA181T/N (21.3%), rtS213T/N (21.3%) and rtV214A (21.3%) for ADV, rtl180M (48%) for ETV, rtM204I for LdT, and rtA194T for tenofovir disoproxil fumarate (TDF).
Evaluation of the dynamic pattern of viral evolution in patients with virological breakthrough during treatment with nucleoside/nucleotide analogs by ultradeep pyrosequencing.
Abstract: Treatment with lamivudine resulted in an increased rate of the viral mutations, rtM204V/I, rtL180M and rtL80I.
Result: Notably, the mutation rate of rtM204I/V was markedly increased at the time of virological breakthrough in eight patients, and this was accompanied by an increased mutation rate of rtL180M and/or rtL80I/V.
Mutational analysis of reverse transcriptase and surface proteins of patients with partial virological response during mono and combination antiviral therapies in genotype D chronic hepatitis B.
Abstract: T54N, L80I/V, I91L/V, L180M, M204I/V, Q215P/S, and F221Y/S showed the highest number of mutations in all groups with different frequencies.
Result: L80I/V was found at the frequencies of 40 and 25% in groups I and III, respectively.
Monitoring of genotypic resistance profile in chronic hepatitis B patients receiving nucleos(t)ide analogues in Huzhou, China.
PMID: 27694733
2016
Journal of infection in developing countries
Abstract: Among patients who harbored rtM204 combination mutations, rtM204I and rtM204V were significantly associated with rtL80I/V and rtL180M, respectively.
Investigation into drug-resistant mutations of HBV from 845 nucleoside/nucleotide analogue-naive Chinese patients with chronic HBV infection.
HBV mutation literature information.
PMID: 
2017
Scientific reports
Browser Board
Co-occurred Entities
Filtrator
ViMRT